

[Add company/entity logo]

Global event on enhancing the sustainability of investment for vaccine manufacturing in Africa.
27-29 June 2023
United Nations Conference Centre, UNECA, Addis Ababa, Ethiopia

Presentation of opportunities for investment and partnerships on vaccines and biopharmaceuticals.

A. Who we are, & what we do

Please provide information on the company, its current portfolio, focus, specialization, and capacity.

Gennex - owning Genvax facility for vaccines production - is a biopharmaceutical company based in Egypt as part of a holding company based in UAE DIFC Dubai that specializes in vaccine development and manufacturing with a particular focus on vaccines used across different NIPs in Egypt and Africa. The company has started establishing a state-of-the-art full production cycle facility that includes advanced technology for the manufacturing, formulation, and quality control of vaccines.

The facility has a capacity of producing up to 150 million doses of vaccines per year per one shift, with the potential to expand further in the future. In addition to its vaccines for all current NIPs, Genvax has also invested in research and development for novel vaccines and a customized strain bank for Africa's different strains.

Genvax's portfolio currently includes:

1. Hep B Vaccine Pedia HBV
2. Ipv
3. Penta
4. HPV
5. PCV
6. QIV
7. ANTI RABIES
8. DT
9. TT
10. Meningitis ACWY13
11. Meningitis AC
12. Rota
13. MMR
14. BCG

Overall, Genvax is committed to using its scientific expertise and state-of-the-art facility to address some of the most pressing public health challenges facing Egypt and the African continent.

[Add company/entity logo]

Our mission at Genvax is to ensure that every person has access to safe, effective, and affordable vaccines that protect them from vaccines preventable diseases. We believe that vaccines are a crucial tool for improving public health and reducing the burden of disease and hospitalization, especially in Africa where the coverage rates for vaccination are still low almost 60% in addition to the WHO roadmap for Africa 2040 enhancing more vaccines localization.

Our vision is to be a leader in vaccine development and to contribute to a world where no one suffers from preventable diseases. We are committed to doing this by developing and manufacturing vaccines locally, using cutting-edge technology and scientific expertise to ensure that our products are of the highest quality.

By localizing vaccine production, we aim to increase vaccine coverage rates in Africa and ensure that people have access to life-saving vaccines when and where they need them. We believe that this will not only improve public health outcomes but also contribute to the economic development of the continent.

In summary, our mission and vision at Genvax are aligned with improving vaccine coverage rates in Africa through localization and using advanced technology to create safe, effective, and affordable vaccines. We are committed to making a positive impact on public health and contributing to a healthier, more prosperous future for the continent.

B. What are we offering

Please provide information on what your company can provide to other partners, such as opportunities for partnership, technology license, training, feasibility study etc?

We are currently offering our genvax academy for africans , Genvax has established the Genvax Academy to provide training and education to individuals who are interested in pursuing a career in the vaccines manufacturing industry. This academy aims to develop and enhance the skills and knowledge needed to succeed in this industry by providing both theoretical and practical training.

The Genvax Academy's curriculum covers a range of topics related to vaccines manufacturing, including vaccine development, vaccine formulation, quality control, and Good Manufacturing Practices (GMPs). In addition to theoretical training, the Genvax Academy also provides hands-on training using state-of-the-art technologies and facilities at the Genvax production facility.

The Genvax Academy's added value lies in its ability to develop a pipeline of highly-skilled and capable professionals who are well-versed in vaccines manufacturing and quality control. The academy provides an opportunity for individuals to gain the necessary knowledge and

[Add company/entity logo]

hands-on experience to succeed in the pharmaceutical industry in general, and vaccines manufacturing in particular.

By investing in this educational academy, Genvax is not only preparing the next generation of vaccines manufacturing professionals, but it is also contributing to the development of the local workforce. This will ultimately help to strengthen the local economy and contribute to the growth of the pharmaceutical and biotechnology sectors in Egypt and Africa as a whole.

Overall, the Genvax Academy is an essential component of our commitment to vaccines manufacturing and our efforts to improve public health outcomes in Africa and beyond.

In addition we are offering the supply of the above mentioned vaccines to any African government , and also our expertise as a team handling and launching all types of vaccines for the past 25 years which should be utilized in getting the African continent together hand in hand to enhance our local production capabilities.

C. What are we looking for

Please provide information on what the company seeks from other partners (businesses, finance, and technology providers)?

We are actually looking to partnerships with governments, tech providers would be a plus as we already have our portfolio but having more suppliers would always be of added value and definitely potential partners would be another pillar.

Contact: ndahaba@gennecs.com
sshawky@gennecs.com
ahossam@eldabatrading.com

Website: www.gennecs.com